Apremilast-induced rise in intraocular pressure in a chronic plaque psoriasis patient

Dear Editor,

A 52-year-old man with chronic plaque psoriasis on topical steroids presented with unsatisfactory disease control. He had large, erythematous scaly plaques on the lower limbs and a few small plaques over the back, with on-and-off joint pain and knee joint swelling. The psoriasis area and severity index (PASI) was 13.8. After routine investigations he was started on oral apremilast, the dose being gradually increased to 30 mg twice a day. After about two months, he complained of redness and watering from eyes. There was no associated headache, nor any significant family history. Ocular examination showed conjunctival congestion. Intraocular pressure (IOP) measured using Goldmann applanation tonometry was 22.7 and 25.2 mm Hg (normal range: 10–21 mm Hg) in his right and left eye, respectively. Cold compresses, carboxymethyl cellulose drops, acyclovir ointment, and dexamethasone-moxifloxacin eye drops were advised which were tapered off in a week. His symptoms subsided within a few days, and he was continued on topical steroids and oral apremilast for psoriasis. However, the relief in ocular symptoms was transient and he presented with similar complaints after three weeks; IOP was still elevated: 25.9 and 26.1 mm Hg, and at four weeks, 25.3 and 27.9 mm Hg in the right and left eye, respectively. It raised suspicion that the IOP rise could be drug induced. On further probing, he reported similar eye symptoms in the past when he received apremilast from another practitioner. As the only new drug added and continued was oral apremilast, and symptoms increased with increasing doses of apremilast, it was suspected as the culprit agent and stopped. It led to symptomatic relief within days. His IOP decreased to 23 and 26 mm Hg on the 4th day and was normal on the 26th day. The patient has been symptom-free for the past six months after the withdrawal of apremilast.

The Food and Drug Administration has approved apremilast for plaque psoriasis and psoriatic arthritis management.¹ Compared to other systemic agents, this drug has fewer side effects, the most common being gastric upset and the most severe being mood disorders and suicidal tendencies. In a case series, 45 cases of increased tearing, possibly due to apremilast, were noted at standard dosing of 30 mg twice daily.² Of these, the dechallenge was positive in 10 cases, rechallenge was positive in three cases and one had a double-positive rechallenge. There are no details of IOP measurement in these cases and it is possible that an apremilast-induced rise in IOP might be responsible. The Naranjo adverse drug reaction probability scale supports the assumption, which scored +9 in our case.³ Although we did not do the rechallenge test, increasing the dose from 20 mg to 30 mg leading to increased symptoms, indirectly supports the causality.

Unilateral glaucoma alerts the wary physician to consider secondary etiologies, which were ruled out in our patient. Thus, the unilateral slight rise in IOP was initially attributed to a mechanical error, and the patient was treated empirically on the lines of conjunctivitis. However, symptom relapse and a rising IOP pointed towards an alternate etiology. Further, evidence towards raised IOP following short-duration topical steroids is lacking.⁴ In our patient, a high-potency topical steroid was applied to < 5% of the body surface area over the thick psoriatic lesions only on the legs. A sight-threatening topical steroid-induced glaucoma has been reported in a patient following chronic use for facial atopic eczema.⁵ The site’s nearness to the eyes, the high absorption rate of facial skin, and chronic use might have caused it.

Phosphodiesterase (PDE) inhibitors have shown cross-reactivity within receptor subtypes in different organs, for example, PDE-5 inhibitors may increase blood flow to the ciliary body, increasing IOP.⁶ Apremilast, a PDE-4 inhibitor, shows some cross-reactivity with other PDE subtypes.⁷ Thus, there is a good chance that apremilast cross-reacts with PDE receptors in the ciliary body, inhibiting them, leading to vasodilation, increasing ciliary blood flow and thus raising IOP.

To conclude, our case highlights a temporal association between oral apremilast administration and rise in IOP, Thus patients should be educated to seek ophthalmology consultation for new-onset eye discomfort or pain and watering who are on apremilast.